These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

473 related items for PubMed ID: 35976170

  • 1. Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study.
    Kawsar A, Edwards C, Patel P, Heywood RM, Gupta A, Mann J, Harland C, Heelan K, Larkin J, Lorigan P, Harwood CA, Matin RN, Fearfield L.
    Br J Dermatol; 2022 Dec; 187(6):981-987. PubMed ID: 35976170
    [Abstract] [Full Text] [Related]

  • 2. Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study.
    Espi M, Teuma C, Novel-Catin E, Maillet D, Souquet PJ, Dalle S, Koppe L, Fouque D.
    Eur J Cancer; 2021 Apr; 147():29-39. PubMed ID: 33607383
    [Abstract] [Full Text] [Related]

  • 3. A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management.
    Lopez AT, Geskin L.
    Oncologist; 2018 Oct; 23(10):1119-1126. PubMed ID: 30018132
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
    Muntyanu A, Netchiporouk E, Gerstein W, Gniadecki R, Litvinov IV.
    J Cutan Med Surg; 2021 Oct; 25(1):59-76. PubMed ID: 32746624
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry.
    Curti B, Daniels GA, McDermott DF, Clark JI, Kaufman HL, Logan TF, Singh J, Kaur M, Luna TL, Gregory N, Morse MA, Wong MKK, Dutcher JP.
    J Immunother Cancer; 2017 Dec 19; 5(1):102. PubMed ID: 29254506
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cutaneous manifestations induced by check point inhibitors in 120 melanoma patients-The European MelSkinTox study.
    L'Orphelin JM, Cassecuel J, Kandolf L, Harwood CA, Tookey P, Junejo MH, Hogan S, Lebbé C, Appalla Z, Kränke TM, Pellacani G, Cerasuolo D, Dujovic B, Del Marmol V, Forschner A, Garbe C, Bataille V, Ressler JM, Sollena P, Dompmartin A, Peris K, Dreno B, And European Association of Dermato-Oncology.
    J Eur Acad Dermatol Venereol; 2023 Apr 12. PubMed ID: 37042810
    [Abstract] [Full Text] [Related]

  • 13. Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Melanoma.
    Pepys J, Stoff R, Ramon-Gonen R, Ben-Betzalel G, Grynberg S, Frommer RS, Schachter J, Asher N, Taliansky A, Nikitin V, Dori A, Shelly S.
    Neurology; 2023 Dec 12; 101(24):e2472-e2482. PubMed ID: 37652699
    [Abstract] [Full Text] [Related]

  • 14. Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study.
    Olsson Ladjevardi C, Koliadi A, Rydén V, Inan El-Naggar A, Digkas E, Valachis A, Ullenhag GJ.
    Cancer Med; 2023 Jun 12; 12(12):13217-13224. PubMed ID: 37132258
    [Abstract] [Full Text] [Related]

  • 15. Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer: A Systematic Review.
    Asdourian MS, Shah N, Jacoby TV, Reynolds KL, Chen ST.
    JAMA Dermatol; 2022 Aug 01; 158(8):933-941. PubMed ID: 35612829
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Generalized morphoea in the setting of combined immune checkpoint inhibitor therapy for metastatic melanoma: A case report.
    Langan EA, Budner K, Zillikens D, Terheyden P.
    Medicine (Baltimore); 2021 Apr 23; 100(16):e25513. PubMed ID: 33879687
    [Abstract] [Full Text] [Related]

  • 19. Risk Factors for the Development of Bullous Pemphigoid in US Patients Receiving Immune Checkpoint Inhibitors.
    Said JT, Liu M, Talia J, Singer SB, Semenov YR, Wei EX, Mostaghimi A, Nelson CA, Giobbie-Hurder A, LeBoeuf NR.
    JAMA Dermatol; 2022 May 01; 158(5):552-557. PubMed ID: 35416925
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.